1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
10qk
10qk
Articles 

Celgene Corp. Reports Operating Results (10-Q)

October 29, 2012 | About:

Celgene Corp. (NASDAQ:CELG) filed Quarterly Report for the period ended 2012-09-30.

Celgene Corporation has a market cap of $32.44 billion; its shares were traded at around $75.2 with a P/E ratio of 17.7 and P/S ratio of 6.7.

Highlight of Business Operations:

Total revenue increased by $169.5 million, or 13.6%, to $1.419 billion for the three-month period ended September 30, 2012 compared to the three-month period ended September 30, 2011, reflecting increases of $75.3 million, or 10.4%, in the United States, and $94.2 million, or 18.0%, in international markets.

Total net product sales for the three-month period ended September 30, 2012 increased by $168.9 million, or 13.9%, to $1.388 billion compared to the three-month period ended September 30, 2011. The increase was comprised of net volume increases of $123.3 million, price increases of $67.8 million and the unfavorable impact from foreign exchange of $22.2 million. The increase in price was primarily due to price increases on REVLIMID® and VIDAZA® in the U.S. market, partly offset by reductions in other markets, mainly in Europe.

Cost of goods sold (excluding amortization of acquired intangible assets): Cost of goods sold (excluding amortization of acquired intangible assets) decreased by $20.0 million to $74.6 million for the three-month period ended September 30, 2012 compared to the three-month period ended September 30, 2011. The decrease was partly due to a $2.9 million decrease in royalties related to a certain product to be divested. In addition, the three-month period ended September 30, 2011 included a $6.9 million inventory step-up amortization adjustment related to sales of ABRAXANE® and approximately $6.0 million in charges related to a certain manufacturing agreement and a product specific inventory adjustment not repeated in the 2012 quarter. These items were partly offset by an increase in 2012 material costs resulting from a higher level of sales activity. As a percent of net product sales, cost of goods sold (excluding amortization of acquired intangible assets) decreased to 5.4% in the three-month period ended September 30, 2012 compared to 7.8% for the three-month period ended September 30, 2011. Excluding the inventory step-up amortization for ABRAXANE®, the cost of goods sold ratio for the three-month period ended September 30, 2011 was 7.2%. The cost of goods sold ratio for 2012 was also favorably impacted by product mix, as lower cost products made up a larger portion of total net sales.

Total revenue increased by $501.1 million, or 14.1%, to $4.059 billion for the nine-month period ended September 30, 2012 compared to the nine-month period ended September 30, 2011, reflecting increases of $239.3 million, or 11.4%, in the United States, and $261.8 million, or 17.9%, in international markets.

Cost of goods sold (excluding amortization of acquired intangible assets): Cost of goods sold (excluding amortization of acquired intangible assets) decreased by $129.4 million to $219.0 million for the nine-month period ended September 30, 2012 compared to the nine-month period ended September 30, 2011. The decrease was primarily due to the 2011 nine-month period inclusion of a $90.3 million inventory step-up amortization adjustment related to sales of ABRAXANE®, an aggregate $13.2 million in costs related to the sale of non-core Abraxis products which were divested in April 2011 and a $14.8 million higher allocation of prepaid royalties related to sales of VIDAZA®. These items were partly offset by an increase in 2012 material costs resulting from a higher level of sales activity. As a percent of net product sales, cost of goods sold (excluding amortization of acquired intangible assets) decreased to 5.5% in the nine-month period ended September 30, 2012 compared to 10.1% for the nine-month period ended September 30, 2011. Excluding the inventory step-up amortization for ABRAXANE®, the cost of goods sold ratio for the nine-month period ended September 30, 2011 was 7.5%. The cost of goods sold ratio for the nine-month period ended September 30, 2012 was favorably impacted by 0.4% from a reduction in royalties due to the expiration of U.S. patents for VIDAZA® and lower cost products comprising a larger portion of total net sales.

Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 3.0/5 (2 votes)

Comments

Please leave your comment:


Select portfolio(s):

  • Loading...

Why you are interested?

Your selection and notes will be stored in your portfolio.

Login to add portfolio
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK